[Tolerance of zidovudine in patients with beta-thalassemia].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to P Boudes.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A 45 years old woman with AL amyloidosis presented with a hypofibrinogenemia (fibrinogen 100 mg/dl) without severe bleeding. There was laboratory evidence of fibrinolysis with shortened euglobulin lysis time, decreased alpha-2 plasmin inhibitor and decreased plasminogen. The mechanism of this primary fibrinolysis remains unclear, since there is no enhancement of the tissue-type plasminogen activator. Analysis of the 8 cases related in the literature of excessive fibrinolysis associated with amyloidosis demonstrated improvement of bleeding manifestations and abnormal fibrinolysis following the administration of antifibrinolytic agents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The interaction of oestrogens with their intra-nuclear receptor is now recognized in its tri-dimensional aspects. A new receptor, ER beta, has been cloned and new non-genomic oestrogen effects have been reported. Hence, a better understanding of physiological mechanisms or of pathophysiological aspects, such as phyto- and xeno-oestrogens' influence on the organism, is possible. New compounds, belonging to the SERM family, are being explored. Raloxifene is now available for the prevention of post-menopausal osteoporosis. Tamoxifen has been associated with a beneficial effect for the primary prevention of breast cancer in a high-risk population. The understanding of genetic susceptibility could contribute, to better define women at risk. A dedicated primary prevention strategy in women with a high risk of breast cancer coupled with early detection through mammography will continue to improve the prognosis of this hormono-dependent cancer.